Premium
Which is the best foot to put forward in recurrent ovarian cancer?
Author(s) -
Rose Peter G.
Publication year - 2011
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.26615
Subject(s) - carboplatin , medicine , docetaxel , ovarian cancer , oncology , chemotherapy , combination chemotherapy , surgery , cancer , cisplatin
This investigation of sequential versus combination chemotherapy for platinum‐sensitive, recurrent ovarian cancer uses a study design that involves giving sequential docetaxel followed by carboplatin. On the basis of the improved progression‐free rate with the combination, use of a nonplatinum agent as the first of the sequential therapies in a platinum‐sensitive patient may not be putting the best foot forward.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom